# NovaBridge Biosciences: Form 20-F for the period ended Dec 31, 2019

- Company: [NovaBridge Biosciences](/companies/nbp.md) (CIK 1778016)
- Form: 20-F
- Filed: 2020-04-29
- Accepted by EDGAR: Apr 29, 2020, 09:13 ET
- Period: 2019-12-31
- Accession: 0001193125-20-124785
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254d20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2019-01-01 to 2019-12-31 | $4.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months, 2019-01-01 to 2019-12-31 | $120.7m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months, 2019-01-01 to 2019-12-31 | $430.0k | us-gaap:InterestExpense |
| Net income | 12 months, 2019-01-01 to 2019-12-31 | −$208.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2019-01-01 to 2019-12-31 | −$28.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2019-01-01 to 2019-12-31 | −$28.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2019-01-01 to 2019-12-31 | 7,381,230 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2019-01-01 to 2019-12-31 | −$124.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2019-01-01 to 2019-12-31 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-12-31 | $163.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-12-31 | $195.5m | us-gaap:AssetsCurrent |
| Total assets | at 2019-12-31 | $249.6m | us-gaap:Assets |
| Current liabilities | at 2019-12-31 | $84.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-12-31 | $96.0m | us-gaap:Liabilities |
| Short-term borrowings | at 2019-12-31 | $7.2m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2019-12-31 | −$292.3m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2019-12-31 | 133,006,644 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254d20f.htm

Filed Apr 29, 2020.
Source: SEC EDGAR, the filing index for accession 0001193125-20-124785. Last ingested by Listed: Nov 6, 2026, 02:19 ET. No prices; not investment advice.